Phacoemulsification Combined With Intravitreal Injection of Ranibizumab Prevent Postoperative Capillary Non-perfusion Zone Progress in Non-proliferative Diabetic Retinopathy
NCT ID: NCT05386160
Last Updated: 2022-05-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
96 participants
INTERVENTIONAL
2022-07-01
2023-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pre-vitrectomy Intravitreal Ranibizumab for Patients With Proliferative Diabetic Retinopathy Combined With Diabetic Macular Edema
NCT04464694
Intravitreal Injection of Ranibizumab Versus Sham Before Vitrectomy in Patients With Proliferative Diabetic Retinopathy
NCT02857491
Anti-VEGF in Real-world
NCT05222633
A Prospective Study of Ranibizumab in the Treatment of Postoperative Recurrent Vitreous Haemorrhage of Diabetic Retinopathy
NCT05248334
Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
NCT01489189
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cataract phacoemulsification combines Ranibizumab
0.05 ml of ranibizumab was injected into the vitreous immediately after the operation
Ranibizumab Injection [Lucentis]
intravitreal injection of Ranibizumab；
Cataract phacoemulsification
0.05 ml of ranibizumab was injected into the vitreous immediately after the operation
Ranibizumab Injection [Lucentis]
intravitreal injection of Ranibizumab；
Phacoemulsification
Phacoemulsification
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ranibizumab Injection [Lucentis]
intravitreal injection of Ranibizumab；
Phacoemulsification
Phacoemulsification
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Commitment to follow the research procedures and cooperate with the implementation of the whole process of research
* No specific gender, 18+ years old
* Diagnosed in line with NPDR,
* Phacoemulsification combined with anti-VEGF therapy is planned
* No obvious surgical contraindications
Exclusion Criteria
* Allergy to anti-VEGF drugs
* Patients with other macular and optic disc diseases
* Patients with meaningful diabetic macular edema
* Patient with surgical complications
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ruijin Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Zijian Yang, Dr
Role: STUDY_DIRECTOR
Department of Ophthalmology, Ruijin Hospital north, Affiliated Medical School, Shanghai Jiaotong University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Ophthalmology, Ruijin Hospital Affiliated Medical,Shanghai Jiaotong University School
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Huiping Yao, Dr.
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RuijinH202201
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.